Standard weekly cetuximab and irinotecan is an effective regimen in heavily pre-treated patients with metastatic colorectal cancer. The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with biweekly cetuximab and irinotecan in patients with pre-treated metastatic colorectal cancer harboring wild-type KRAS. A total of 30 patients will be enrolled at four medical institutions. The primary endpoint is response rate. The secondary endpoints include adverse events, progression-free survival and overall survival. The pharmacokinetics of cetuximab will also be evaluated in five patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyq026 | DOI Listing |
Publication Analysis
Top Keywords
cetuximab irinotecan
12
metastatic colorectal
12
colorectal cancer
12
combination chemotherapy
8
chemotherapy biweekly
8
biweekly cetuximab
8
pre-treated metastatic
8
cancer harboring
8
harboring wild-type
8
wild-type kras
8
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!